Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28854543 | 0.98 | NOS1 (0.44) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL31148280 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL14553409 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL622240 | 0.83 | NOS1 (0.52) | NOS1AXLMETAP2IDO1 | |
| SCHEMBL29860402 | 0.80 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL3498472 | 0.80 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL29793750 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL30860972 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL15687490 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 | |
| SCHEMBL3497181 | 0.76 | NOS1 (0.46) | NOS1AXLMETAP2IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4716685-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2026-03-12 | — | — | US | disclosed |
| WO-2024240726-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-11-28 | — | — | WO | disclosed |
| EP-3814360-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIVERSITY | 2024-07-11 | — | — | US | disclosed |
| CN-114853723-B | Preparation and application of indole compound BTK inhibitor | 药雅科技(上海)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-115141176-B | Acetylenic indole FGFR inhibitor and preparation method and application thereof | 药雅科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| CN-114853723-A | Preparation and application of indole compound BTK inhibitor | 药雅科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3814360-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| WO-2018092047-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | JOINT STOCK COMPANY "BIOCAD" (RU) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070906-A1 | IMIDAZO[4,5-C]PYRIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | TLR1, TLR6, TLR8 | NOS1 3135/4885AXL 688/4885METAP2 2335/4885 |
| US-20240228489-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM3, CHRM2 | NOS1 2108/4885AXL 2103/4885METAP2 3210/4885 |
| US-11685746-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | NOS1 4588/4885AXL 4798/4885METAP2 2095/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | NOS1 1757/4885AXL 2268/4885METAP2 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.